May 16, 2022 -- From academic research centers to small biotechs to large pharmaceutical companies, the numbers of biosamples and measurements are growing exponentially with these organizations having critical needs when it comes to sample fulfillment, processing, storage, and analysis to minimize time to discovery.
David Lewandowski, Azenta Life Sciences' director of business development for cell and gene therapy (CGT), observes there are a lot of different workflows around sample management and characterization, with new therapeutics requiring the collection, processing, and analysis of thousands of biosamples.
"Over the last decade, we've been acquiring different services, products, and capabilities to support life sciences" including sample management and characterization "across the translational lifecycle from research and discovery, even into manufacturing and distribution," Lewandowski told ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco. "Somebody that's in research and discovery is going to have very different needs than somebody that's in late-stage clinical phase trials."
Watch the video below to learn more.
Copyright © 2022 scienceboard.net